NASDAQ:CRVS - Corvus Pharmaceuticals, Inc.
$3.95
 $0.06
+1.54%
4:00PM EDT
2019-04-18
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CRVS     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 64   203. 85   241. 91  
42 stocks rank:  3. 67 K 1. 44 K 1. 05 K
# analyst opinions:  3. 00   14. 51   13. 97  
mean recommendation:  1. 30   2. 09   2. 01  

quick ratio:  16. 36   5. 27   1. 81  
current ratio:  16. 45   5. 62   2. 25  

target price low:  11. 00   84. 80   115. 21  
target price avg:  4. 24   111. 51   137. 51  
target price high:  4. 77   135. 81   157. 84  
1-yr high:  13. 73   114. 23   138. 78  
last close:  3. 95   87. 66   116. 69  
50-day avg:  4. 18   95. 54   123. 44  
200-day avg:  6. 81   94. 25   121. 11  
1-yr low:  3. 29   72. 78   98. 34  
volume:  69. 87 K 4. 11 M 8. 07 M
50-day avg volume:  92. 87 K 2. 76 M 5. 02 M
200-day avg volume:  89. 41 K 2. 92 M 4. 59 M

1-day return:  1. 54 % -0. 41 % 0. 07 %
this week return:  0. 77 % -5. 74 % -4. 11 %
12-wk return:  -1. 00 % 1. 61 % -0. 05 %
52-wk return:  -62. 52 % 3. 12 % 8. 78 %

enterprise value (EV):  1. 24 M 48. 94 B 114. 64 B
market cap:  115. 84 M 43. 07 B 104. 73 B
EBITDA:  -48. 38 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 03   4. 22   12. 73  
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -46. 94 M 2. 20 B 4. 20 B

shares outstanding:  29. 33 M 571. 70 M 1. 24 B
shares:  11. 31 M 571. 81 M 1. 23 B
shares short:  1. 37 M 10. 17 M 13. 00 M
shares short prior month:  1. 20 M 9. 54 M 17. 33 M
short ratio:  13. 02   5. 41   3. 28  
short % of float:  10. 00 % 5. 45 % 2. 38 %
total cash/share:  3. 91   11. 14   9. 33  
total cash:  114. 60 M 6. 71 B 7. 15 B
free cash flow:  -24. 89 M 3. 58 B 2. 96 B
operating cash flow:  -40. 99 M 4. 15 B 4. 30 B

book value:  3. 76   12. 78   26. 92  
price/book:  1. 05   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  16. 35 % --- ---
1-yr mean volatility:  -0. 31 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 71   2. 40   4. 10  
forward EPS:  -1. 89   3. 97   7. 13  
P/E:  -2. 32   13. 63   22. 72  
forward P/E:  -2. 09   -15. 95   13. 99  
PE/G:  0. 16   -1. 65   -1. 32  
growth:  -14. 28 % 127. 12 % 29. 61 %
earnings high:  -0. 39   1. 00   1. 66  
earnings avg:  -0. 40   0. 77   1. 53  
earnings low:  -0. 41   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -28. 88 % -2. 75 % 4. 55 %
return on equity:  -48. 10 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  1. 09   1. 25   0. 93  
sharpe (1yr):  -1. 25   0. 37   0. 70  

held % insiders:  5. 09 % 6. 39 % 3. 38 %
held % institutions:  86. 18 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : CRVS
.    + 0.281 =         0.281 :: INITIAL WEIGHT
.   + 32.004 =        32.286 :: spline projection addition
.    x 1.431 =        46.214 :: industry recommendation factor
.    x 2.697 =       124.637 :: symbol recommendation factor
.    x 0.997 =       124.277 :: return on assets factor
.    x 0.995 =        123.68 :: return on equity factor
.    x 2.925 =       361.721 :: current ratio factor
.    x 1.032 =       373.313 :: quick ratio factor
.    x 1.038 =       387.384 :: short ratio factor
.     x 2.01 =       778.834 :: price-to-book factor
.    x 2.137 =       1664.61 :: P/E weight
.    x 1.576 =      2623.044 :: PE/G factor
.    x 1.503 =       3941.84 :: beta factor
.    x 0.639 =      2517.393 :: sharpe factor
.    x 2.564 =      6453.664 :: target low factor
.    x 1.091 =       7039.63 :: target mean factor
.    x 1.046 =      7361.282 :: target high factor
.     x 1.31 =      9642.454 :: industry 2-weeks return factor
.    x 0.979 =      9438.247 :: overall "drift" factor
.    x 0.837 =       7895.21 :: largest single-day jump factor
.    x 0.076 =       596.766 :: low price factor
.      x 1.0 =       596.669 :: factor hist industry gain for week 16
.   cubeRoot =         8.419 :: reduced to standardize
.    - 23.24 =         0.644 :: add/subtract for performance
.                      0.644 :: FINAL WEIGHT for NASDAQ:CRVS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org